Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Gray markets sprang up to supply Byetta as a fad-diet drug, a preview to the current Wegovy and Ozempic craze
Beginning with the EMPA-REG OUTCOME trial in 2015, multiple glucose-lowering therapies have demonstrated a reduction in cardiovascular outcomes in people both with and without T2D
One big impediment is the expense of these medications, which are frequently more expensive than typical anti-diabetic therapies
Advanced lab testing to look at IGF-1, cholesterol, blood sugar, liver enzymes, and other hormones
If you have not lost at least 5% of your starting weight by this point, schedule a discussion with your healthcare provider about next steps rather than continuing unchanged
